These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29747831)

  • 1. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support.
    Vincent F; Rauch A; Loobuyck V; Robin E; Nix C; Vincentelli A; Smadja DM; Leprince P; Amour J; Lemesle G; Spillemaeker H; Debry N; Latremouille C; Jansen P; Capel A; Moussa M; Rousse N; Schurtz G; Delhaye C; Paris C; Jeanpierre E; Dupont A; Corseaux D; Rosa M; Sottejeau Y; Barth S; Mourran C; Gomane V; Coisne A; Richardson M; Caron C; Preda C; Ung A; Carpentier A; Hubert T; Denis C; Staels B; Lenting PJ; Van Belle E; Susen S
    J Am Coll Cardiol; 2018 May; 71(19):2106-2118. PubMed ID: 29747831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pulsatility on shear-induced extensional behavior of Von Willebrand factor.
    Wang Y; Nguyen KT; Ismail E; Donoghue L; Giridharan GA; Sethu P; Cheng X
    Artif Organs; 2022 May; 46(5):887-898. PubMed ID: 34866200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired von Willebrand syndrome in paediatric patients during mechanical circulatory support.
    Kubicki R; Stiller B; Kroll J; Siepe M; Beyersdorf F; Benk C; Höhn R; Grohmann J; Fleck T; Zieger B
    Eur J Cardiothorac Surg; 2019 Jun; 55(6):1194-1201. PubMed ID: 30590475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of pulsatility with continuous-flow left ventricular assist devices and the significance of the arterial endothelium in von-Willebrand factor production and degradation.
    Giridharan GA; Berg IC; Ismail E; Nguyen KT; Hecking J; Kirklin JK; Cheng X; Sethu P
    Artif Organs; 2023 Apr; 47(4):640-648. PubMed ID: 36404709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased RPM reduces von Willebrand factor degradation with the EVAHEART LVAS: implications for device-specific LVAD management.
    Bartoli CR; Kang J; Motomura T
    J Card Surg; 2020 Jul; 35(7):1477-1483. PubMed ID: 32652785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced continuous-flow left ventricular assist device speed does not decrease von Willebrand factor degradation.
    Kang J; Zhang DM; Restle DJ; Kallel F; Acker MA; Atluri P; Bartoli CR
    J Thorac Cardiovasc Surg; 2016 Jun; 151(6):1747-1754.e1. PubMed ID: 26971377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Models for Translational Investigations of Left Ventricular Assist Device-Associated von Willebrand Factor Degradation.
    Restle DJ; Zhang DM; Hung G; Howard JL; Kallel F; Acker MA; Atluri P; Bartoli CR
    Artif Organs; 2015 Jul; 39(7):569-75. PubMed ID: 25810063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ADAMTS-13 by Doxycycline Reduces von Willebrand Factor Degradation During Supraphysiological Shear Stress: Therapeutic Implications for Left Ventricular Assist Device-Associated Bleeding.
    Bartoli CR; Kang J; Restle DJ; Zhang DM; Shabahang C; Acker MA; Atluri P
    JACC Heart Fail; 2015 Nov; 3(11):860-9. PubMed ID: 26454844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Von Willebrand factor profile predicts clinical outcomes in patients on mechanical circulatory support.
    Oezpeker C; Zittermann A; Baurichter D; Morshuis M; Prohaska W; Kassner A; Erkilet G; Gummert J; Milting H
    J Card Surg; 2018 Oct; 33(10):693-702. PubMed ID: 30199919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolysis and von Willebrand factor degradation in mechanical shuttle shear flow tester.
    Shiraishi Y; Tachizaki Y; Inoue Y; Hayakawa M; Yamada A; Kayashima M; Matsumoto M; Horiuchi H; Yambe T
    J Artif Organs; 2021 Jun; 24(2):111-119. PubMed ID: 33559766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation.
    Deconinck SJ; Nix C; Barth S; Bennek-Schöpping E; Rauch A; Schelpe AS; Roose E; Feys HB; Pareyn I; Vandenbulcke A; Muia J; Vandenbriele C; Susen S; Meyns B; Tersteeg C; Jacobs S; De Meyer SF; Vanhoorelbeke K
    J Thromb Haemost; 2022 Dec; 20(12):2797-2809. PubMed ID: 36128768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
    Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
    Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and In Vitro Evidence That Left Ventricular Assist Device-Induced von Willebrand Factor Degradation Alters Angiogenesis.
    Bartoli CR; Zhang DM; Hennessy-Strahs S; Kang J; Restle DJ; Bermudez C; Atluri P; Acker MA
    Circ Heart Fail; 2018 Sep; 11(9):e004638. PubMed ID: 30354363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishing a method for in vitro investigation of mechanical parameters causing acquired von Willebrand syndrome in ventricular assist devices.
    Egger C; Maas J; Hufen T; Schmitz-Rode T; Steinseifer U
    Artif Organs; 2013 Sep; 37(9):833-9. PubMed ID: 23834027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic von Willebrand factor degradation with a left ventricular assist device occurs via two distinct mechanisms: mechanical demolition and enzymatic cleavage.
    Bartoli CR; Restle DJ; Zhang DM; Acker MA; Atluri P
    J Thorac Cardiovasc Surg; 2015 Jan; 149(1):281-9. PubMed ID: 25439775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Left Ventricular Assist Device Design Reduces von Willebrand Factor Degradation: A Comparative Study Between the HeartMate II and the EVAHEART Left Ventricular Assist System.
    Bartoli CR; Kang J; Zhang D; Howard J; Acker M; Atluri P; Motomura T
    Ann Thorac Surg; 2017 Apr; 103(4):1239-1244. PubMed ID: 27717422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients.
    Crow S; Chen D; Milano C; Thomas W; Joyce L; Piacentino V; Sharma R; Wu J; Arepally G; Bowles D; Rogers J; Villamizar-Ortiz N
    Ann Thorac Surg; 2010 Oct; 90(4):1263-9; discussion 1269. PubMed ID: 20868825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. von Willebrand factor disruption and continuous-flow circulatory devices.
    Proudfoot AG; Davidson SJ; Strueber M
    J Heart Lung Transplant; 2017 Nov; 36(11):1155-1163. PubMed ID: 28756118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stress and Exposure Time on von Willebrand Factor Degradation.
    Jhun CS; Siedlecki C; Xu L; Lukic B; Newswanger R; Yeager E; Reibson J; Cysyk J; Weiss W; Rosenberg G
    Artif Organs; 2019 Feb; 43(2):199-206. PubMed ID: 30374981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of shear stress on the size, structure, and function of human von Willebrand factor.
    Chan CH; Pieper IL; Fleming S; Friedmann Y; Foster G; Hawkins K; Thornton CA; Kanamarlapudi V
    Artif Organs; 2014 Sep; 38(9):741-50. PubMed ID: 25234758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.